Skip to main content
SpringerLink
Log in

Inflammatory muscle disease: Clinical presentation and assessment of patients

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Muscle weakness and muscle fatigue are the most common manifestations in patients with idiopathic inflammatory myopathies (ie, myositis), but other organs are frequently involved such as skin, lungs, joints, and the heart. These could occur before, simultaneously with, or after the onset of muscle symptoms. One tool to structure outcome measure is the International Classification of Functioning, Disability, and Health. Measures of “disability” can be divided into impairment and activity limitation/participation restriction. Most of the available outcome measures for myositis could be classified as measures of impairment, such as muscle strength, serum levels of muscle enzymes, and pulmonary function tests. Measures of activity limitation/participation restriction are also important, such as the myositis activities profile, the visual analog scale to assess impact on general well-being, and the generic short form-36 to capture impact on health-related quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193–208.

    Article  PubMed  CAS  Google Scholar 

  2. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487–1498.

    Article  PubMed  CAS  Google Scholar 

  3. Plotz PH, Rider LG, Targoff IN, et al.: NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995, 122:715–724.

    PubMed  CAS  Google Scholar 

  4. Miller FW, Rider LG, Chung YL, et al.: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001, 40:1262–1273.

    Article  CAS  Google Scholar 

  5. World Health Organization: The international classification of functioning, disability and health. Geneva: World Health Organization; 2001.

    Google Scholar 

  6. IMACS website. https://dir-apps.niehs.nih.gov./imacs Accessed June 7, 2007.

  7. Alexanderson H, Broman L, Tollback A, et al.: Functional index-2: Validity and relability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006, 55:114–122.

    Article  PubMed  Google Scholar 

  8. Alexanderson H, Dastmalchi M, Lundberg IE: Patients with chronic inflammatory myopathies have reduced muscle endurance rather than reduced muscle strength. Arthritis Rheum 2006, 54(Suppl):S658.

    Google Scholar 

  9. Gerami P, Schope JM, McDonald L, et al.: Asystematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006, 54:597–613.

    Article  PubMed  Google Scholar 

  10. Suda T, Fujisawa T, Enomoto N, et al.: Interstitial lung disease associated with amyopathic dermatomyositis. Eur Respir J 2006, 28:1005–1012.

    Article  PubMed  CAS  Google Scholar 

  11. Fathi M, Dastmalchi M, Rasmussen E, et al.: Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004, 63:297–301.

    Article  PubMed  CAS  Google Scholar 

  12. Lundberg IE: The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 2006, 45(Suppl 4):iv18–iv21.

    Article  Google Scholar 

  13. Finsterer J, Stollberger C, Avanzini M, et al.: Restrictive cardiomyopathy in dermatomyositis. Scand J Rheumatol 2006, 35:229–232.

    Article  PubMed  CAS  Google Scholar 

  14. Ohata S, Shimada T, Shimizu H, et al.: Myocarditis associated with polymyositis diagnosed by gadolinium-DTPA enhanced magnetic resonance imaging. J Rheumatol 2002, 29:861–862.

    PubMed  Google Scholar 

  15. Allanore Y, Vignaux O, Arnaud L, et al.: Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006, 65:249–252.

    Article  PubMed  CAS  Google Scholar 

  16. Brouwer R, Hengstman GJ, Vree Egberts W, et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60:116–123.

    Article  PubMed  CAS  Google Scholar 

  17. Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360–374.

    CAS  Google Scholar 

  18. Sato S, Kuwana M, Hirakata M: Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) 2007, 46:842–845.

    Article  CAS  Google Scholar 

  19. Hengstman GJ, Vree Egberts WT, Seelig HP, et al.: Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann Rheum Dis 2006, 65:242–245.

    Article  PubMed  CAS  Google Scholar 

  20. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al.: Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006, 65:1635–1638.

    Article  PubMed  CAS  Google Scholar 

  21. Targoff IN, Mamyrova G, Trieu EP, et al.: A novel autoantibody to 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682–3689.

    Article  PubMed  CAS  Google Scholar 

  22. Cherin P, Pelletier S, Teixiera A, et al.: Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467–474.

    Article  PubMed  CAS  Google Scholar 

  23. Danieli MG, Malcangi G, Palmieri C, et al.: Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002, 61:37–41.

    Article  PubMed  CAS  Google Scholar 

  24. Hengstman GJ, van den Hoogen FH, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary results. Eur Neurol 2003, 50:10–15.

    Article  PubMed  CAS  Google Scholar 

  25. Wiesinger GF, Quittan M, Aringer M, et al.: Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998, 37:196–200.

    Article  PubMed  CAS  Google Scholar 

  26. Wiesinger GF, Quittan M, Graninger, et al.: Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998, 37:1338–1342.

    Article  PubMed  CAS  Google Scholar 

  27. Varju C, Petho E, Kutas R, et al.: The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003, 17:83–87.

    Article  PubMed  Google Scholar 

  28. Spector SA, Lemmer JT, Koffman BM, et al.: Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997, 20:1242–1248.

    Article  PubMed  CAS  Google Scholar 

  29. Badrising UA, Maat-Schieman ML, Ferrari MD, et al.: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51:369–372.

    Article  PubMed  CAS  Google Scholar 

  30. Arnardottir S, Alexanderson H, Lundberg IE, et al.: Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003, 35:31–35.

    Article  PubMed  Google Scholar 

  31. Josefson A, Romanus E, Carlsson J: A functional index in myositis. J Rheumatol 1996, 23:1380–1384.

    PubMed  CAS  Google Scholar 

  32. Alexanderson H, Stenstrom CH, Lundberg I: The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000, 29:295–301.

    Article  PubMed  CAS  Google Scholar 

  33. Vencovsky J, Jarosova K, Machacek S, et al.: Cyclosporine A versus methotrexate in treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95–102.

    Article  PubMed  CAS  Google Scholar 

  34. Heikkila S, Viitanen JV, Kautiainen H, et al.: Rehabilitation in myositis. Physiotherapy 2001, 87:301–309.

    Article  Google Scholar 

  35. Newcomer KL, Krug HE, Mahowald ML: Validity and reliability of the timed-stands test for patients with rheumatoid arthritis and other rheumatic diseases. J Rheumatol 1993, 20:21–27.

    PubMed  CAS  Google Scholar 

  36. Agarwal S, Kiely PD: Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis. Rheumatol 2006, 45:874–879.

    Article  CAS  Google Scholar 

  37. Rider LG, Feldman BM, Perez MD, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997, 40:1976–1983.

    Article  PubMed  CAS  Google Scholar 

  38. Rider LG: Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am 2002, 28:935–977.

    Article  Google Scholar 

  39. Huber AM, Hicks JE, Lachenbruch PA, et al.: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001, 28:1106–1111.

    PubMed  CAS  Google Scholar 

  40. Isenberg DA, Allen E, Farewell V, et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004, 43:49–54.

    Article  PubMed  CAS  Google Scholar 

  41. Park JH, Vital TL, Ryder NM, et al.: Magnetic resonance imaging and p-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994, 37:736–746.

    Article  PubMed  CAS  Google Scholar 

  42. Weber MA, Weber MA, Jappe U, et al.: Contrast-enhanced ultrasound in dermatomyositis and polymyositis. J Neurol 2006, 253:1625–1632.

    Article  PubMed  Google Scholar 

  43. Weber MA, Krix M, Jappe U, et al.: Pathologic skeletal muscle perfusion in patients with myositis: detection with quantitative contrast-enhanced US—initial results. Radiology 2006, 238:640–649.

    Article  PubMed  Google Scholar 

  44. Fries JF, Spitz P, Kraines RG, et al.: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137–145.

    Article  PubMed  CAS  Google Scholar 

  45. Alexanderson H, Lundberg IE, Stenstrom CH: Development of the myositis activities profile—validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 2002, 29:2386–2392.

    PubMed  Google Scholar 

  46. World Health Organization: International classification of impairment, disability and handicap. Beta-2 draft, full version. Geneva: World Health Organization; 1999.

    Google Scholar 

  47. Verhoeven AC, Boers M, van der Linden S: Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. J Rheumatol 2000, 27:2801–2809.

    PubMed  CAS  Google Scholar 

  48. Alemo Munters L, van Vollenhoven R, Alexanderson H: Measurement properties of the Swedish MACTAR. Arthritis Rheum 2006, 54(Suppl):S503.

    Google Scholar 

  49. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey: conceptual framework and item selection. Med Care 1992, 30:473–483.

    Article  PubMed  Google Scholar 

  50. Sultan SM, Ioannou Y, Moss K, et al.: Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002, 41:22–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Unit, Karolinska University Hospital, Solna, SE-171 76, Stockholm, Sweden

    Ingrid E. Lundberg MD, PhD

Authors
  1. Helene Alexanderson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingrid E. Lundberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingrid E. Lundberg MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alexanderson, H., Lundberg, I.E. Inflammatory muscle disease: Clinical presentation and assessment of patients. Curr Rheumatol Rep 9, 273–279 (2007). https://doi.org/10.1007/s11926-007-0044-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0044-8

Keywords

Search

Navigation